Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

1,969JPY
19 Jul 2018
Change (% chg)

¥-24 (-1.20%)
Prev Close
¥1,993
Open
¥1,999
Day's High
¥2,005
Day's Low
¥1,963
Volume
1,106,500
Avg. Vol
1,336,142
52-wk High
¥2,748
52-wk Low
¥1,835

Latest Key Developments (Source: Significant Developments)

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Mitsubishi Tanabe Pharma completes purchase of NeuroDerm
Wednesday, 18 Oct 2017 

Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<>>.Purchase plan was announced on July 24.  Full Article

FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS
Tuesday, 30 Aug 2016 

Mitsubishi Tanabe Pharma <4508.T> : FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS . FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS .Says if approved, medicine will be commercialized, under brand name Radicava, through newly formed Mt Pharma America, Inc.  Full Article